RLYB (Rallybio) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rallybio Debt-to-Asset?

Rallybio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.15 Mil. Rallybio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Rallybio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $68.11 Mil. Rallybio's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Rallybio Debt-to-Asset Historical Data

The historical data trend for Rallybio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rallybio Debt-to-Asset Chart

Rallybio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

Rallybio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Rallybio's Debt-to-Asset

For the Biotechnology subindustry, Rallybio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rallybio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rallybio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rallybio's Debt-to-Asset falls into.

Save

Rallybio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rallybio's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.154	+	0)	/	68.108
	=	0.00

Rallybio's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.154	+	0)	/	68.108
	=	0.00

Rallybio (NAS:RLYB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Rallybio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rallybio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rallybio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rallybio Corp (NAS:RLYB) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

234 Church Street, Suite 1020, New Haven, CT, USA, 06510

Website

https://www.rallybio.com

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Executives

5am Partners V, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jonathan I Lieber	officer: See Remarks	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Wendy Chung	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Hui Liu	director	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Christine A Nash	director	C/O RALLYBIO CORPORATION, 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510